Physician

Ryan Chua Chua, M.D.

According to 2025 Medicare claims, Ryan Chua, M.D. (NPI: 1659534501) practices pulmonary disease in the Worcester, MA market, with the plurality of this provider's patient population coming from Worcester, MA. This provider's primary affiliated billing organization is MASS LUNG & ALLERGY, PC. (NPI: 1679734545; TIN: 262792629) and primary practice location at 01453-2205. Chua is affiliated with the UMASS Memorial Accountable Care Organization, INC. (ACO ID: A2598), participating under the MSSP model.

Chua's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,111 traditional Medicare patients, billed 2,604 HCPCS/CPT codes, and received $268,149 in Medicare payments. The top billing code was 99291 (Critical care, first 30-74 minutes). Part D data shows 1,770 prescription claims across 299 beneficiaries totaling $634,883 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 2,452 claims. Open Payments data shows 87 records totaling $1,922. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $287,750 to $634,883. For DME billing, reported payments rose steadily, from $64,908 to $103,347.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	736	2,263	$206,593
2016	868	2,461	$217,112
2017	1,034	2,677	$223,968
2018	1,120	2,853	$286,426
2019	1,132	2,836	$275,733
2020	940	2,239	$225,783
2021	938	2,280	$244,432
2022	943	2,338	$241,522
2023	1,045	2,510	$266,509
2024	1,111	2,604	$268,149

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	310	1,555	$287,750
2016	298	1,765	$456,823
2017	322	1,994	$591,178
2018	283	1,618	$436,942
2019	295	1,587	$590,017
2020	280	1,711	$599,434
2021	304	1,896	$639,926
2022	294	1,832	$699,440
2023	285	1,550	$659,501
2024	299	1,770	$634,883

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	487	1,518	$77,285
2016	798	2,532	$123,439
2017	921	2,576	$106,727
2018	894	2,558	$108,768
2019	782	2,040	$110,298
2020	674	1,945	$120,588
2021	832	2,340	$130,812
2022	797	2,388	$111,692
2023	755	2,447	$133,171
2024	841	2,452	$150,216

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99291	Critical care, first 30-74 minutes	139	373	$171
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	184	218	$138
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	104	116	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	581	727	$96
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	231	665	$93

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	188	8,250	$172,725
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	92	4,440	$91,319
Breo Ellipta	Fluticasone/Vilanterol	94	3,840	$49,730
Nucala	Mepolizumab	11	308	$47,069
Spiriva Respimat	Tiotropium Bromide	44	1,740	$29,567

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	41	$31,178
A7031	Face mask interface, replacement for full face mask, each	N	61	165	$15,295
A7030	Full face mask used with positive airway pressure device, each	N	64	173	$14,368
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	12	$12,065
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	28	156	$11,659

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	87	$1,922	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ryan Chua Chua, M.D.?

Tedicare shows public-source Medicare data for Ryan Chua Chua, M.D. (NPI 1659534501), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ryan Chua Chua, M.D. have ACO affiliation data?

Ryan Chua Chua, M.D. is shown with ACO affiliation data for UMASS Memorial Accountable Care Organization, INC. (MSSP, ACO ID A2598).

What billing organization is linked to Ryan Chua Chua, M.D.?

Ryan Chua Chua, M.D. is linked to MASS LUNG & ALLERGY, PC. (billing NPI 1679734545) in the available physician profile data.

Does Ryan Chua Chua, M.D. have Open Payments data?

Ryan Chua Chua, M.D. has 87 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.